Short-term therapeutic effect of three different neoadjuvant chemotherapy regimens on triple negative breast cancer

Objective The compare the short-term therapeutic effect of three different neoadjuvant chemotherapy regimens on triple negative breast cancer(TNBC). Methods From April 2013 to April 2015, 120 patients with TNBC were randomly selected, according to the different wasy of neoadjuvant chemotherapy, the patients were divided into group A, group B and group C, with 40 cases in geach group. The patients in group A were treated with docetaxel, epirubicin and cyclophosphamide(TAC), and the patients in group B were treated with docetaxel and cyclophosphamide (TC), and the patients in group C were treated with 5-fluorouracil, epirubicin, cyclophosphamide (CEF), the curative effects and clinical adverse reactions of three groups of patients after chemotherapy were analyzed. Results The efficacy rate was 87.5% in group A, which was significantly higher than that in group B(85.0%) and group C(82.5%), the differences were statistically significant (P 0.05); after chemotherapy for three weeks, the tumor size decreased in group A and group B was significantly higher than that in group C, the difference was significant (P<0.05). Conclusions The short-term therapeutic effect of docetaxel, epirubicin and cyclophosphamide on TNBC is better than docetaxel and cyclophosphamide, fluorouracil, epirubicin, cyclophosphamide, it can prolong the disease-free survival time of patients, improve the survival rate, no allergic reactions induced by drugs are found in the treatment, it is worthy of clinical research. Key words: Triple negative breast cancer; Short-term effect; Neoadjuvant chemotherapy; Adverse reactions